REGN REGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 740.50 $ 15.48 (2.14 %)    

Thursday, 20-Nov-2025 15:24:28 EST
QQQ $ 588.88 $ -22.79 (-3.73 %)
DIA $ 459.81 $ -6.87 (-1.47 %)
SPY $ 656.01 $ -16.89 (-2.51 %)
TLT $ 89.21 $ 0.22 (0.25 %)
GLD $ 374.81 $ -0.37 (-0.1 %)
$ 702.75
$ 721.80
$ 741.69 x 15
$ 740.60 x 9
$ 721.15 - $ 752.96
$ 475.17 - $ 796.57
1,383,591
na
73.77B
$ 0.71
$ 16.11
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-28-2025 09-30-2025 10-Q
2 08-01-2025 06-30-2025 10-Q
3 04-29-2025 03-31-2025 10-Q
4 02-05-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-05-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-06-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 02-07-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-08-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-07-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-07-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-03-2018 03-31-2018 10-Q
32 02-08-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 02-09-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tech-stocks-fall-despite-nvidias-beat-walmart-jumps-6-whats-moving-markets-thursday

Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lif...

 regeneron-wins-fda-nod-for-eylea-hd-with-reduced-injection-schedule-for-patients-with-vision-loss

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across...

 wells-fargo-maintains-equal-weight-on-regeneron-pharmaceuticals-raises-price-target-to-700

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price ...

 regeneron-pharmaceuticals-gets-fdas-approval-for-its-eylea-hd-injection-8-mg-to-treat-macular-edema-following-retinal-vein-occlusion

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYL...

 fear-of-an-ai-bubble-this-sector-is-quietly-surging-while-tech-sinks

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

 governor-hochul-announces-regeneron-to-invest-more-than-2-billion-into-saratoga-county-facility-creating-1000-new-jobs

https://www.governor.ny.gov/news/governor-hochul-announces-regeneron-invest-more-2-billion-saratoga-county-facility-creating

 wall-street-falls-on-us-government-reopening-day-bitcoin-slides-to-100000-whats-moving-markets-thursday

Risk sentiment deteriorated sharply on Thursday despite federal agencies reopening after the longest government shutdown in U.S...

 crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its...

 reported-saturday-regeneron-reports-robust-anti-clotting-effects-for-regn7508cat-and-regn9933a2-in-total-knee-replacement-patients-with-no-clinically-relevant-bleeding

Proof-of-concept trials confirm robust anti-clotting effects for Regeneron's two mechanistically-distinct antibodies agains...

 ubs-maintains-neutral-on-regeneron-pharmaceuticals-raises-price-target-to-660

UBS analyst Trung Huynh maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $5...

 regeneron-pharmaceuticals-trial-data-from-liberty-afrs-aims-phase-3-study-shows-dupixent-improves-signs-symptoms-of-allergic-fungal-rhinosinusitis-reduces-sinus-opacification-nasal-congestion-and-nasal-polyps

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the pivotal...

 rbc-capital-maintains-sector-perform-on-regeneron-pharmaceuticals-raises-price-target-to-708

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the pr...

 wells-fargo-maintains-equal-weight-on-regeneron-pharmaceuticals-raises-price-target-to-615

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price ...

 cantor-fitzgerald-maintains-overweight-on-regeneron-pharmaceuticals-raises-price-target-to-740

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the pr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION